Table 1

Baseline characteristics of the randomised study population

Randomised patients (n = 199)
INTERCOM (n = 102)Usual care (n = 97)
Gender (% male)71%71%
Age (years)65.9 (8.8)67.2 (8.9)
Co-morbidities (n)1.6 (1.6)1.5 (1.4)
Exacerbations in 12 months before trial (n)1.2 (1.4)1.0 (1.5)
COPD hospital admissions in 12 months before trial (n)0.24 (0.52)0.23 (0.50)
Current smokers (%)33%24%
Smoking (pack-years)38.5 (25.2)36.1 (26.4)
FEV1 (% predicted)58 (17)60 (15)
FEV1/FVC (%)49 (11)51 (12)
% patients FEV1 >50% predicted72%65%
% patients FEV1 ⩽50% predicted28%35%
SGRQ Total score*39 (15)38 (15)
SGRQ Activity score55 (18)56 (19)
SGRQ Symptom score45 (19)41 (22)
SGRQ Impact score27 (16)25 (16)
Total MRC score†1.7 (1.0)1.5 (0.9)
6-min walk test (% predicted)80 (13)83 (12)
Wmax (% predicted)60 (19)61 (17)
HGF (% predicted)77 (17)78 (18)
QPT (% predicted)95 (21)92 (23)
Fat-free mass (kg/m2)17.1 (2.0)17.6 (1.9)
BMI (kg/m2)26.1 (4.4)27.3 (4.7)
  • Data are n (%) or mean (SD).

  • *St George’s Respiratory Questionnaire: a higher score indicates a worse quality of life.

  • †Modified MRC dyspnoea score.

  • BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FFM, fat-free mass; FVC, forced vital capacity; HGF, handgrip force; 6MWD, 6-minute walking distance; QPT, isometric quadriceps peak torque; SGRQ, St George’s Respiratory Questionnaire; Wmax, peak exercise capacity.